Over last 3M, ABL has underperformed CNXINFRA by 18%. The concerns surrounding SBIM stake sale and likely event of ABL giving cash exit (in case of distress valuation) may have led to this underperformance. ABL as per exit term has no mandatory cash settlement clause. At best there could be asset transfer which may be stake dilutive for ABL and result in investment write down. Going by consensus ACL valuation impact could be Rs 7.3bn (Rs 26/sh). We maintain BUY. Key risks (1) Delay in SBI Macquarie deal closure; (2) Dip in traffic revenue from BOT projects; (3) Delay in ADs. We maintain BUY on ABL with reduced SOTP of Rs 220/sh. We have cut our standalone EPC multiple from 15x to 12x to factor in concerns surrounding ACL monetization and likely impact on ABL stake dilution in ACL below 61%, in case of suboptimal valuation bids.